Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Oct. 18-31. Deal Watch is supported by deal intelligence from Strategic Transactions.
Publicly listed Australian biotech Novogen Ltd. announced Oct. 31 that it has licensed GDC-0084, a small-molecule inhibitor of the...








